摘要 |
A pharmaceutical composition for the sustained release of an effective amount of a selective 5-hydroxytryptamine 3 (5-HT<SUB>3</SUB>) receptor antagonist for the prevention, reduction or alleviation of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following a course of emetogenic chemotherapy, wherein the composition is administered by subcutaneous injection, the composition comprising a 5-HT<SUB>3</SUB> receptor antagonist, a semi-solid delivery vehicle and a pharmaceutically acceptable liquid excipient; wherein the composition, when administered in a single dosage, provides a controlled release of the 5-HT<SUB>3</SUB> receptor antagonist and prolonging the release of the 5- HT<SUB>3</SUB> receptor antagonist that tracks the profile of the incidence of vomiting. |
申请人 |
A.P. PHARMA, INC.;SHAH, DEVANG;BARR, JOHN;BAXTER, BRIAN;HELLER, JORGE |
发明人 |
SHAH, DEVANG;BARR, JOHN;BAXTER, BRIAN;HELLER, JORGE |